Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pertuzumab, trastuzumab, and hyaluronidase

(per-TOO-zoo-mab tras-TOO-zoo-mab … HY-al-yoo-RAH-nih-days)
A combination of three drugs used with other drugs to treat adults with HER2-positive breast cancer. It is used before surgery in patients with locally advanced, inflammatory, or early-stage breast cancer and after surgery in patients with early-stage breast cancer who have a high risk that their cancer will recur (come back). It is also used to treat patients with breast cancer that has spread to other parts of the body and has not already been treated with anti-HER2 therapy or chemotherapy. Pertuzumab and trastuzumab bind to a protein called HER2, which is found on some breast cancer cells. Pertuzumab and trastuzumab may block HER2 and help the immune system kill cancer cells. Hyaluronidase allows pertuzumab and trastuzumab to be given by injection under the skin. Pertuzumab, trastuzumab, and hyaluronidase can be given in less time than pertuzumab or trastuzumab alone, which are given as infusions. Also called Phesgo.
More Information
Search NCI's Dictionary of Cancer Terms